Pfizer, Inc. News

Do you have an interest in the products developed by Pfizer, Inc., or are you interested in the performance of the company? If you are you should register for the free Pfizer, Inc. news email from Wiser. Pfizer, Inc. is an American-based pharmaceutical company that researches, develops and manufactures medicines and vaccines. The products developed by the company are used all over the world. They include leading brands like Lipitor, Zithromax and Viagra. The company was founded in 1849 and today is one of the largest pharmaceutical companies in the world. Its current chairman and CEO is Ian Reed. Most analysts expect Pfizer, Inc. to expand through acquisitions over the coming years. The Wiser daily Pfizer, Inc. news email covers this news as well as analysis on the performance of the company, and details about its products. These articles come from the best sources around the web and are delivered in a comprehensive but simple to use format. Sign up today.

Recent Pfizer, Inc. News Coverage
 
Your Weekly Recommendations Monday, February 19, 2018
 
Recommended for you
Wall Street opens lower as financial, tech stocks weigh
Reuters • Noel Randewich
Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q4 2017 Update
Seeking Alpha • John Vincent
Futures rise, setting stocks on firm ground for the week
Reuters • Noel Randewich
New Tax Cuts Will Save Billions. But for Whom?
Fortune Magazine • Geoff Colvin
Intercept Pharmaceuticals: What The Latest Earnings Foretell?
Seeking Alpha • Biosci Capital Partners
FDA Investigating Misuse, Abuse of Gabapentinoids
MedPage Today • Joyce Frieden
Syndax Pharmaceuticals Undervalued On Coming Data Readouts
Seeking Alpha • William Meyers
How Pharma Can Minimize Political Risk From Its Repatriation Windfall
Forbes • Contributor, Standish Fleming
Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial
Reuters • Ludwig Burger
Why I Recently Bought Johnson & Johnson
Seeking Alpha • Big Ticket Fund Managers
 
Recommended for You
Elections & Polls, Finance
Wall Street opens lower as financial, tech stocks weigh
ReutersNoel Randewich
NEW YORK () - The S&P 500 rose marginally on Friday to mark its biggest weekly increase in five years, although earlier gains evaporated after the indictment of Russians for meddling in the 2016 presidential election sent investors into defensive mode before...
Share
Finance, Investment Industry
Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q4 2017 Update
Seeking AlphaJohn Vincent
Summary Prem Watsa's 13F portfolio value increased ~16% from $1.22B to $1.42B this quarter. Fairfax Financial's largest five stakes are Blackberry, Resolute Forest Products, Kennedy Wilson, Intrepid Potash, and USG. They together account for ~85% of the US long assets. The 13F...
Share
Elections & Polls, Pfizer, Inc.
Futures rise, setting stocks on firm ground for the week
ReutersNoel Randewich
NEW YORK () - The S&P 500 rose marginally on Friday to mark its biggest weekly increase in five years, although earlier gains evaporated after the indictment of Russians for meddling in the 2016 presidential election sent investors into defensive mode before...
Share
Economic Policy, Labor Policy
New Tax Cuts Will Save Billions. But for Whom?
Fortune MagazineGeoff Colvin
Headlines dripped with scorn when Kimberly-Clark (kmb, +0.27%) announced in January that it would lay off 5,000 to 5,500 employees. The company “celebrates the Trump tax cuts with massive layoffs, share buybacks,” said Salon, and will “use savings from tax cuts to...
Share
Health Finance, Pfizer, Inc.
Intercept Pharmaceuticals: What The Latest Earnings Foretell?
Seeking AlphaBiosci Capital Partners
Summary For fiscal 2017, Intercept reported increasingly significant but not substantial sales for Ocaliva. Updated label of Ocaliva has the optimized dosing to push for more revenues growth this year. Phase 3 (REGENERATE) trial in NASH fibrosis to report data in 1H...
Share
Health Care Industry, Pfizer, Inc.
FDA Investigating Misuse, Abuse of Gabapentinoids
MedPage TodayJoyce Frieden
WASHINGTON -- The FDA is looking at whether gabapentinoids are an addiction threat, FDA Commissioner Scott Gottlieb, MD, said Thursday. Gabapentinoids such as pregabalin (Lyrica) as well as the original agent gabapentin (Neurontin) are approved to treat a variety of conditions, including...
Share
Biotechnology, Cancer
Syndax Pharmaceuticals Undervalued On Coming Data Readouts
Seeking AlphaWilliam Meyers
Summary Syndax recently was added to the Nasdaq Biotechnology Index. Syndax has a cancer therapy in Phase 3. Valuation seems low considering pipeline potential. Syndax Pharmaceuticals (SNDX) is a clinical stage biotechnology company with a pipeline of pharmaceuticals Syndax came up in...
Share
Health Care Industry, Pfizer, Inc.
How Pharma Can Minimize Political Risk From Its Repatriation Windfall
ForbesContributor, Standish Fleming
Part I – The Problem: Too Much Money, Too Few Drugs A tidal wave of cash due from the repatriation of overseas reserves as a result of tax reform threatens to exacerbate pharma’s already serious excess money problem. The country expects companies...
Share
Cancer, Epidemiology
Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial
ReutersLudwig Burger
FRANKFURT () - Merck KGaA and Pfizer received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies. In the late stage trial of Bavencio, the drug could not be shown...
Share
Actelion Pharmaceuticals, Finance
Why I Recently Bought Johnson & Johnson
Seeking AlphaBig Ticket Fund Managers
Summary Recently initiated a position in JNJ at $129. Take advantage of the recent dip in a blue chip dividend aristocrat. Recent earnings have renewed my trust in the company's long term growth plan backed by a strong pipeline that will fuel...
Share